Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen

Clinical Immunology

Volumn 114, Issue 3 SPEC. ISS., 2005, Pages 307-319

  Hess, Allan D ^a   Thoburn, Christopher J ^a   Miura, Yuji ^a   Bright, Emilie C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

C neu; CLIP; Co stimulatory receptors; Cytokine polarization; Invariant chain peptide; MHC class II; Peptide modification; Self antigen; T cell repertoire diversity; Tumor associated self antigen

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CHIMERIC PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; LIGAND; LYSYLPROLYLVALYLSERYLPROLYLMETHIONYLARGINYLMETHIONYLALANYLTHREONYLPROLYL LEUCYLLEUCYLMETHIONYLARGINYLPROLYLLEUCYLSERYLMETHIONYLASPARTIC ACID; LYSYLPROLYLVALYLSERYLPROLYLMETHIONYLTHREONYLLEUCYLGLUTAMYLARGINYLPROLYL LYSYLTHREONYLLEUCYLSERYLPROLYLLYSYLASPARAGINYLGLYCYLVALINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; THREONYLLEUCYLGLUTAMYLARGINYLPROLYLLYSYLTHREONYLLEUCYLSERYLPROLYLLYSYL ASPARAGINYLGLYCYLVALINE; THREONYLLEUCYLGLUTAMYLARGINYLPROLYLLYSYLTHREONYLLEUCYLSERYLPROLYLLYSYL ASPARAGINYLGLYCYLVALYLARGINYLPROLYLLEUCYLSERYLMETHIONINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL BASED GENE THERAPY; CELL COMMUNICATION; CELL COMPARTMENTALIZATION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA FLANKING REGION; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; FEMALE; GENE CONTROL; GENE MUTATION; GENETIC VARIABILITY; IMMUNIZATION; IMMUNOGENICITY; MOLECULE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MODIFICATION; RAT; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; UPREGULATION;

EID: 13844296639     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2004.11.004     Document Type: Article

References (55)

1. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
2. J. Kappler, U. Staerz, and J. White Self-tolerance eliminates T cells specific for MLS-modified products of the MHC complex Nature 332 1988 35 39
3. J. Kappler, U. Staerz, and J. White T cell tolerance by clonal elimination in the thymus Cell 49 1987 273 281
4. M.-G. Roncarolo, and K. Levings The role of T regulatory cells in controlling autoimmunity Curr. Opin. Immunol. 12 2000 676 683
5. S. Saskaguchi Regulatory T cells: key controllers of immunologic self-tolerance Cell 101 2000 455 468
6. E.M. Shevach Regulatory T cells in autoimmunity Annu. Rev. Immunol. 18 2000 423 450
7. A.N. Houghton Cancer antigens: immune recognition of self and altered self J. Exp. Med. 180 1994 1 4
8. E. Sotomayor, I. Borrello, and H. Levitsky Tolerance and cancer: a critical issue in tumor immunology Crit. Rev. Oncog. 7 1996 433 456
9. C.G. Ioannides, and T.L. Whiteside T cell recognition of human tumors: implications for molecular immunotherapy of cancer Clin. Immunol. Immunopathol. 66 1993 91 102
10. M.L. Disis, S.M. Pupa, J.R. Gralow, R. Dittadi, S. Menard, and M.A. Cheever High titer Her-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer J. Clin. Oncol. 15 1997 3363 3367
11. M.L. Disis, J.W. Smith, A.E. Murphy, W. Chen, and M.A. Cheever In vitro generation of human cytolytic T-cells specific for peptides derived from the Her-2/neu proto-oncogene protein Cancer Res. 54 1994 1071 1079
12. I. Kawashima, S.J. Hudson, U. Tsai, S. Southwood, K. Takesako, E. Appella, M. Sette, and E. Celis The multiepitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors Hum. Immunol. 59 1998 1 14
13. E.M. Jaffe, A. Lazenby, J. Meurer, F. Marshall, K.M. Hauda, R. Counts, H. Hurwitz, J.W. Simons, H.I. Levitsky, and D.M. Pardoll Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials J. Immunother. 18 1 1995 1 9
14. D.M. Pardoll Paracrine cytokine adjuvants in cancer immunotherapy Annu. Rev. Immunol. 13 1995 399 415
15. P. Chaturvedi, R. Hengeveld, M.H. Zechel, E. Lee-Chan, and B. Singh The functional role of class II-associated invariant chain peptide (CLIP) in its ability to variably modulate immune responses Int. Immunol. 12 2000 757 765
16. S. Adams, F. Albercico, J. Alsina, E.R. Smith, and R.E. Humphreys Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic binding peptide binding to cell surface MHC class II molecules Arzneim.-Forsch. 47 1997 1069 1077
17. K. Frauwirth, and N. Shastri Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains Immunology 102 2001 405 415
18. P. Cresswell Assembly, transport and function of MHC class II molecules Annu. Rev. Immunol. 12 1994 259 293
19. P. Ghosh, M. Amaya, E. Mellins, and D.C. Wiley The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3 Nature 378 1995 457 462
20. L.J. Stern, J.H. Brown, T.S. Jardetzky, J.C. Gorga, R.G. Urban, J.L. Strominger, and D.C. Wiley Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide Nature 368 1994 215 220
21. A.D. Hess, C.J. Thoburn, W. Chen, Y. Miura, and E. Van der Wall The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen Clin. Immunol. 101 2001 67 76
22. G. Malcherek, C. Wirblich, N. Willcox, H.-G. Rammensee, J. Trowsdale, and A. Melms MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation Eur. J. Immunol. 28 1998 1524 1533
23. O. Rotzschke, K. Falk, J. Mack, J.M. Lau, G. Jung, and J.L. Strominger Conformational variants of class II/MHC peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes Proc. Natl. Acad. Sci. U. S. A. 96 1999 7445 7550
24. R.G. Urban, R.M. Chicz, and J.L. Strominger Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH J. Exp. Med. 180 1994 751 755
25. A.D. Hess, C.J. Thoburn, W. Chen, and E.C. Bright Unexpected T-Cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules Transplantation 75 2001 1361 1367
26. C.J. Thoburn, Y. Miura, E.C. Bright, and A.D. Hess Functional divergence of antigen-specific T-lymphocyte responses in syngeneic graft-versus-host disease Biol. Blood Marrow Transplant. 10 2004 591 603
27. Y. Miura, C.J. Thoburn, E.C. Bright, M.L. Phelps, T. Shin, E.C. Matsui, W.H. Matsui, S. Arai, E.J. Fuchs, G.B. Vogelsang, R.J. Jones, and A.D. Hess Association of Foxp3 regulatory gene expression with graft-versus-host disease Blood 104 2004 2187 2193
28. A.D. Hess, C.J. Thoburn, and L. Horwitz Promiscuous recognition of major histocompatibility complex determinants in cyclosporine-induced syngeneic graft-versus-host disease Transplantation 65 1998 785 791
29. M.L. Disis, S.M. Pupa, J.R. Gralow, R. Dittadi, S. Menard, and M.A. Cheever High titer Her-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer J. Clin. Oncol. 15 1997 3363 3367
30. W. Chen, C.J. Thoburn, Y. Miura, M. Sommer, R. Hruban, Z. Qian, W. Baldwin, and A.D. Hess Autoimmune-mediated vasculopathy Clin. Immunol. 100 2001 57 70
31. Y. Miura, C.J. Thoburn, E. Bright, W. Chen, S. Nakao, and A.D. Hess Cytokine and chemokine profiles in autologous graft-versus-host disease: interleukin 10 and interferon γ may be critical mediators for the development of autologous GVHD Blood 100 2002 2650 2658
32. Y. Miura, C.J. Thoburn, E.C. Bright, M. Sommer, S. Lefell, M. Ueda, S. Nakao, and A.D. Hess Characterization of the T cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T cell response in the development of autologous GVHD Blood 98 2001 868 876
33. P. Matzinger The JAM test: a simple assay for DNA fragmentation and cell death J. Immunol. Methods 145 1991 185 194
34. R.E. Humphreys, S. Adams, G. Koldzic, B. Nedelescu, E. von-Hofe, and M. Xu Increasing the potency of MHC class II-presented epitopes by linkage to Ii-key peptide Vaccine 18 2000 2693 2697
35. F. Bischof, W. Wienhold, C. Wirblich, G. Malcherek, O. Zevering, A.M. Kruisbeek, and A. Melms Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes Proc. Natl. Acad. Sci. U. S. A. 98 2001 12168 12173
36. K. Frauwirth, and N. Shastric Mutation of the invariant chain transmembrane region inhibits Ii degradation, prolongs association with MHC class II, and selectively disrupts antigen presentation Cell. Immunol. 209 2001 97 108
37. J. Van Bergen, M. Camps, R. Offringa, C.J.M. Melief, F. Ossendorp, and F. Koning Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide Cancer Res. 60 2000 6427 6433
38. H. Groux, M. Bigler, J.E. de Vries, and M.G. Roncarolo Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells J. Immunol. 160 1998 3188 3193
39. B.R. Blazar, P.A. Taylor, S. Smith, and D.A. Vallera Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts Blood 85 1995 842 851
40. D.H. Fowler, J. Breglio, G. Nagel, M.A. Eckhaus, and R.E. Gress Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease J. Immunol. 157 1995 4811 4819
41. D.H. Fowler, K. Kurasawa, A. Hesebeek, and P.A. Cohen Cells of the Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction: regulation of cytokines and CD8+ lymphoid engraftment J. Immunol. 152 1994 1004 1112
42. F. Moschella, M.N. Ombra, G. Del Pozzo, and J. Guardiola Administration of different antigenic forms of altered peptide ligands derived from HIV-1 RTase influences their effects on T helper cell activation Hum. Immunol. 64 2003 1 8
43. K.R. Ryan, L.K. McNeill, C. Dao, P.E. Jensen, and B.D. Evavold Modification of peptide interaction with MHC creates TCR partial agonists Cell. Immunol. 227 2004 70 78
44. E.I. Buzas, A. Hanyecz, Y. Murad, F. Hudecz, E. Rajnavolgyi, K. Mickez, and T.T. Glant Differential recognition of altered peptide ligands distinguishes two functionally discordant (arthritogenic and nonarthritogenic) autoreactive T cell hybridoma clones J. Immunol. 171 2003 3025 3033
45. H. Bour-Jordan, and J.A. Bluestone CD28 function: a balance of costimulatory and regulatory signals J. Clin. Immunol. 22 2002 1 8
46. D. Salomon, and J.A. Bluestone Complexities of CD28/B7 system of T cell co-stimulation Annu. Rev. Immunol. 14 1996 233 258
47. P. Taylor, C.J. Lees, S. Fournier, J.P. Allison, A.H. Sharpe, and B.R. Blazar B7 expression of T cells down-regulates immune responses through CTLA-4 ligation via R-T interactions J. Immunol. 172 2004 34 39
48. G. Ferlazzo, C. Semino, M. Meta, F. Procopio, B. Morandi, and G. Melioli T lymphocytes express B7 family molecules following interaction with dendritic cells and acquire bystander costimulatory properties Eur. J. Immunol. 32 2002 3092 3101
49. M.F. Najoukas, S. Southwood, S.J. Mathiews, E. Appella, A. Sette, and J. Miller T cell recognition of flanking residues of murine invariant chain-derive CLIP peptide bound to MHC class II Cell 188 1998 49 54
50. M.D. Hesse, A.Y. Karulin, B.O. Boehm, P.V. Lehmann, and M. Tary-Lehmann A T cell clone's avidity is a function of its activation state J. Immunol. 167 2001 1353 1361
51. A.Y. Karulin, M.D. Hesse, H.C. Yip, and P.V. Lehmann Indirect IL-4 pathway in type 1 immunity J. Immunol. 168 2002 545 553
52. W. Chen, C. Thoburn, and A.D. Hess Characterization of the pathogenic autoreactive T Cells in cyclosporine-induced syngeneic graft-vs-host disease J. Immunol. 161 1998 7040 7046
53. A. Murtaza, V.K. Kuchroo, and G.J. Freeman Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands Int. Immunol. 11 1999 407 416
54. T. Kato, and H. Nariuchi Polarization of naïve CD4+ T cells towards the Th1 subset by CTLA-4 costimulation J. Immunol. 164 2000 3554 3562
55. O. Alpan, E. Bachelder, E. Isil, H. Arnheiter, and P. Matzinger "Educated" dendritic cells act as messengers from memory to naïve T helper cells Nat. Immunol. 5 2004 615 622